Previous 10 | Next 10 |
THE WOODLANDS, Texas, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced the issuance and sale of an additional 2,526,540 shares of its common stock, par value $0.001 (the “ Common Stock ”)...
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2022 Earnings Conference Call August 2, 2022 17:00 ET Company Participants Mike Kelly - Investor Relations Lonnel Coats - Chief Executive Officer Jeff Wade - President & Chief Financial Officer Craig Granowitz - Sen...
Lexicon Pharmaceuticals press release ( NASDAQ: LXRX ): Q2 GAAP EPS of -$0.16 in-line. Revenue of $0.04M (-80.0% Y/Y) misses by $0.06M . “We received acceptance last week of our New Drug Application (NDA) for sotagliflozin for the treatment of heart failure ...
Sotagliflozin New Drug Application for Heart Failure Accepted for Review by FDA, with PDUFA Action Date Anticipated in May 2023 LX9211 Phase 2 Clinical Proof-of-Concept Achieved in Painful Diabetic Neuropathy, Promising Novel Mechanism of Action in Neurop...
Lexicon Pharmaceuticals ( NASDAQ: LXRX ) is scheduled to announce Q2 earnings results on Tuesday, August 2nd, after market close. The consensus EPS Estimate is -$0.16 and the consensus Revenue Estimate is $0.1M (-50.0% Y/Y). For further details see: Lexicon Pharm...
THE WOODLANDS, Texas, July 29, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its second quarter 2022 financial results on Tuesday, August 2, 2022 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET...
Gainers: REX American Resources ( REX ) +195% . SQL Technologies ( SKYX ) +64% . Athersys ( ATHX ) +66% . JAKKS Pacific ( JAKK ) +34% . Aridis Pharmaceuticals ( ARDS ) +33% . Better Therapeutics ( BTTX ) +32% . Co...
Gainers: Better Therapeutics BTTX +43% . GeoVax Labs ( GOVX ) +22% . Aridis Pharmaceuticals ( ARDS ) +19% . Comera Life Sciences ( CMRA ) +13% . Gracell Biotechnologies ( GRCL ) +13% . Losers: Community Health Systems ( CYH ...
Lexicon Pharmaceuticals ( NASDAQ: LXRX ) priced its earlier announced underwritten public offering of 16.8M shares, par value $0.001, at $2.5/share. Gross proceeds are expected to be ~$42.1M. Underwriters granted 30-day option to purchase up to an additional 2.53M...
THE WOODLANDS, Texas, July 28, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced the pricing of its previously announced underwritten public offering of 16,843,600 shares of its common stock, par value $0.001 (the ...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00...
Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease THE WOODLANDS, Texas, July 16, 20...
New analysis of the pivotal Phase 3 SOLOIST-WHF trial provides additional evidence of positive economic impact on hospitals participating in various alternative payment models (APM) Findings consistent with two peer-reviewed studies published in June 2024 THE WOODLANDS, Texa...